{"id":"risedronate-sodium-actonel","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Gastrointestinal upset (nausea, dyspepsia, abdominal pain)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Musculoskeletal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"<1","effect":"Osteonecrosis of the jaw (rare)"},{"rate":"<1","effect":"Atypical femoral fractures (rare)"}]},"_chembl":{"chemblId":"CHEMBL1654","moleculeType":"Small molecule","molecularWeight":"305.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisphosphonates like risedronate are taken up by osteoclasts during bone resorption and inhibit the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway essential for osteoclast function and survival. This leads to decreased bone turnover and increased bone mineral density. The drug is particularly effective at reducing vertebral and hip fracture risk in osteoporosis by slowing bone loss.","oneSentence":"Risedronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:15.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postmenopausal osteoporosis (treatment and prevention)"},{"name":"Glucocorticoid-induced osteoporosis"},{"name":"Paget's disease of bone"},{"name":"Osteoporosis in men"}]},"trialDetails":[{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT04922333","phase":"PHASE3","title":"Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-28","conditions":"Bone Loss","enrollment":200},{"nctId":"NCT04152551","phase":"PHASE4","title":"Effects of Bisphosphonates on OI-Related Hearing Loss","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-11-02","conditions":"Osteogenesis Imperfecta","enrollment":100},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT05630768","phase":"PHASE4","title":"Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-01-03","conditions":"Postmenopausal Osteoporosis","enrollment":149},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT00092040","phase":"PHASE3","title":"A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03-18","conditions":"Osteoporosis, Postmenopausal","enrollment":936},{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":"Postmenopausal Osteoporosis","enrollment":1053},{"nctId":"NCT00567606","phase":"NA","title":"Prevention of Osteoporosis in Breast Cancer Survivors","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-04-01","conditions":"Postmenopausal Osteoporosis","enrollment":249},{"nctId":"NCT02186600","phase":"PHASE3","title":"Heartland Osteoporosis Prevention Study","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-02-01","conditions":"Osteopenia","enrollment":276},{"nctId":"NCT04879420","phase":"","title":"Replication of the VERO Osteoporosis Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-10-29","conditions":"Osteoporosis","enrollment":12757},{"nctId":"NCT03861091","phase":"PHASE2","title":"Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-07-12","conditions":"Lung Neoplasm","enrollment":84},{"nctId":"NCT05803681","phase":"NA","title":"CCEF in the Treatment of Acute VFFs: Randomized Controlled Trial","status":"COMPLETED","sponsor":"University of Bari Aldo Moro","startDate":"2015-01-01","conditions":"Vertebral Fracture, Osteoporotic Fractures","enrollment":70},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT00594334","phase":"PHASE4","title":"Effect of Actonel on Periodontal Health of Postmenopausal Women","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-01","conditions":"Periodontal Disease","enrollment":""},{"nctId":"NCT05346419","phase":"NA","title":"Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients","status":"COMPLETED","sponsor":"Hospital Regional 1o de Octubre","startDate":"2021-07-01","conditions":"Postmenopausal Osteoporosis, Hypovitaminosis D, Hyperparathyroidism","enrollment":33},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":"Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma","enrollment":684815},{"nctId":"NCT00445575","phase":"PHASE2, PHASE3","title":"Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2007-07-22","conditions":"Fibrous Dysplasia of Bone","enrollment":80},{"nctId":"NCT01950169","phase":"NA","title":"Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2004-12","conditions":"Hip Fracture","enrollment":79},{"nctId":"NCT03411902","phase":"PHASE4","title":"Weight Loss With Risedronate for Bone Health","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-15","conditions":"Bariatric Surgery Candidate, Bone Loss, Weight Loss","enrollment":24},{"nctId":"NCT00452439","phase":"PHASE3","title":"A Study of Actonel for the Prevention of Bone Loss","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-02","conditions":"Leukemia, Lymphoma","enrollment":72},{"nctId":"NCT00089843","phase":"PHASE2, PHASE3","title":"Bone Loss in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-06","conditions":"Anorexia Nervosa","enrollment":77},{"nctId":"NCT00919711","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-09-01","conditions":"Osteoporosis","enrollment":870},{"nctId":"NCT01406444","phase":"NA","title":"IGF-1 and Bone Loss in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":"Anorexia Nervosa, Osteopenia, Osteoporosis","enrollment":148},{"nctId":"NCT00354302","phase":"PHASE3","title":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-24","conditions":"Breast Cancer, Osteoporosis","enrollment":497},{"nctId":"NCT00887354","phase":"PHASE4","title":"A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Osteoporosis","enrollment":224},{"nctId":"NCT01709110","phase":"PHASE4","title":"VERtebral Fracture Treatment Comparisons in Osteoporotic Women","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Postmenopausal Osteoporosis","enrollment":1366},{"nctId":"NCT01675297","phase":"PHASE4","title":"Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2011-07-04","conditions":"Osteoporosis","enrollment":1053},{"nctId":"NCT02106442","phase":"","title":"36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-05-13","conditions":"Osteoporosis","enrollment":579},{"nctId":"NCT04034199","phase":"PHASE3","title":"Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid","status":"UNKNOWN","sponsor":"Kwong Wah Hospital","startDate":"2019-08-15","conditions":"Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia","enrollment":40},{"nctId":"NCT02106455","phase":"","title":"Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08-01","conditions":"Osseous Paget's Disease","enrollment":315},{"nctId":"NCT00266708","phase":"PHASE1, PHASE2","title":"Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2002-10","conditions":"Renal Transplant Osteodystrophy","enrollment":60},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":"Postmenopausal Osteoporosis","enrollment":86},{"nctId":"NCT02089997","phase":"","title":"Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-05-27","conditions":"Osteoporosis","enrollment":3304},{"nctId":"NCT02744482","phase":"PHASE3","title":"Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis","status":"TERMINATED","sponsor":"University Hospital, Limoges","startDate":"2016-05","conditions":"Prosthesis Loosening","enrollment":3},{"nctId":"NCT03208582","phase":"PHASE2","title":"Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?","status":"COMPLETED","sponsor":"Sheffield Children's NHS Foundation Trust","startDate":"2017-04-01","conditions":"Osteogenesis Imperfecta","enrollment":13},{"nctId":"NCT01904110","phase":"PHASE4","title":"To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Osteoporosis","enrollment":196},{"nctId":"NCT01575873","phase":"PHASE3","title":"Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-28","conditions":"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor","enrollment":795},{"nctId":"NCT00405392","phase":"PHASE4","title":"Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-22","conditions":"Osteoporosis, Postmenopausal","enrollment":365},{"nctId":"NCT00244907","phase":"PHASE1","title":"Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women","status":"COMPLETED","sponsor":"Purdue University","startDate":"2006-01","conditions":"Osteoporosis, Osteopenia","enrollment":23},{"nctId":"NCT00859027","phase":"PHASE4","title":"Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer","status":"COMPLETED","sponsor":"UConn Health","startDate":"2003-01","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT00666627","phase":"PHASE2","title":"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-04","conditions":"Post-menopausal Osteoporosis","enrollment":410},{"nctId":"NCT01882400","phase":"PHASE4","title":"Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy","status":"COMPLETED","sponsor":"Gilles Boire","startDate":"2001-05","conditions":"Osteoporosis, Muscular Dystrophy, Cystic Fibrosis","enrollment":11},{"nctId":"NCT00485953","phase":"PHASE4","title":"Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Susan L. Greenspan","startDate":"2007-09","conditions":"Bone Loss, Osteoporosis, Breast Cancer","enrollment":109},{"nctId":"NCT01038011","phase":"PHASE2","title":"Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2004-06","conditions":"Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT00043069","phase":"PHASE3","title":"Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-11","conditions":"Osteoporosis, Prostate Cancer","enrollment":71},{"nctId":"NCT02148848","phase":"PHASE4","title":"Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2013-06","conditions":"Osteoporotic Fractures, Femoral Neck Fracture","enrollment":86},{"nctId":"NCT00377234","phase":"PHASE4","title":"A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Post Menopausal Osteoporosis","enrollment":356},{"nctId":"NCT00054418","phase":"PHASE3","title":"Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-03","conditions":"Breast Cancer, Osteoporosis","enrollment":216},{"nctId":"NCT00216060","phase":"PHASE3","title":"Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy","status":"TERMINATED","sponsor":"Christopher Sweeney, MBBS","startDate":"2003-10","conditions":"Metastatic Prostate Cancer","enrollment":63},{"nctId":"NCT00118508","phase":"NA","title":"The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-05","conditions":"Osteoporosis","enrollment":87},{"nctId":"NCT00869622","phase":"PHASE4","title":"Antiepileptic Drugs and Osteoporotic Prevention Trial","status":"COMPLETED","sponsor":"Boston VA Research Institute, Inc.","startDate":"2006-06","conditions":"Epilepsy, Bone Loss, Osteoporosis","enrollment":80},{"nctId":"NCT00918749","phase":"PHASE2","title":"Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-05","conditions":"Postmenopausal Osteoporosis","enrollment":205},{"nctId":"NCT00221299","phase":"PHASE4","title":"Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-09","conditions":"Osteoporosis","enrollment":60},{"nctId":"NCT00772395","phase":"PHASE4","title":"Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Danderyd Hospital","startDate":"2006-04","conditions":"Bone Loss","enrollment":78},{"nctId":"NCT01611571","phase":"PHASE3","title":"Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis","status":"COMPLETED","sponsor":"Columbia University","startDate":"2003-12","conditions":"Osteoporosis","enrollment":31},{"nctId":"NCT00859703","phase":"PHASE3","title":"Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-11","conditions":"Breast Cancer, Menopause, Osteopenia","enrollment":20},{"nctId":"NCT00837746","phase":"","title":"Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2003-04","conditions":"Osteoporosis","enrollment":29},{"nctId":"NCT00778154","phase":"","title":"Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-01","conditions":"Postmenopausal Osteoporosis","enrollment":105},{"nctId":"NCT00106028","phase":"PHASE3","title":"Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-11","conditions":"Osteogenesis Imperfecta","enrollment":143},{"nctId":"NCT00247273","phase":"PHASE3","title":"A Study of Monthly Risedronate for Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2005-10","conditions":"Postmenopausal Osteoporosis","enrollment":1294},{"nctId":"NCT00541658","phase":"PHASE3","title":"A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-10","conditions":"Postmenopausal Osteoporosis","enrollment":923},{"nctId":"NCT00577395","phase":"PHASE4","title":"Bone Microarchitecture in Osteopenic Postmenopausal Women","status":"TERMINATED","sponsor":"Warner Chilcott","startDate":"2008-07","conditions":"Osteoporosis","enrollment":13},{"nctId":"NCT00577837","phase":"PHASE2","title":"Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-04","conditions":"Postmenopausal","enrollment":370},{"nctId":"NCT00577850","phase":"PHASE1","title":"Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2002-11","conditions":"Osteopenia, Osteoporosis","enrollment":32},{"nctId":"NCT00699777","phase":"PHASE1","title":"Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2008-01","conditions":"Osteoporosis","enrollment":96},{"nctId":"NCT00145704","phase":"NA","title":"Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density","status":"TERMINATED","sponsor":"State University of New York - Upstate Medical University","startDate":"2002-06","conditions":"Osteopenia","enrollment":6},{"nctId":"NCT01806792","phase":"PHASE3","title":"Post-menopausal Women Osteoporosis(Phase III)","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2009-11","conditions":"Postmenopausal Women Osteoporosis","enrollment":150},{"nctId":"NCT00324714","phase":"PHASE3","title":"Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS","status":"WITHDRAWN","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-02","conditions":"Breast Cancer, Osteoporosis","enrollment":""},{"nctId":"NCT00365456","phase":"PHASE3","title":"Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-07","conditions":"Osteoporosis","enrollment":407},{"nctId":"NCT00447915","phase":"PHASE3","title":"Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-03","conditions":"Primary Osteoporosis","enrollment":1265},{"nctId":"NCT00103740","phase":"PHASE3","title":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-04","conditions":"Paget's Disease of Bone","enrollment":185},{"nctId":"NCT00051636","phase":"PHASE3","title":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2001-01","conditions":"Paget's Disease of Bone","enrollment":172},{"nctId":"NCT00503399","phase":"PHASE3","title":"Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-07","conditions":"Osteoporosis","enrollment":92},{"nctId":"NCT00351091","phase":"PHASE2","title":"Risedronate in Postmenopausal Women With Low Bone Density","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-11","conditions":"OSTEOPOROSIS, POSTMENOPAUSAL","enrollment":150},{"nctId":"NCT00426777","phase":"PHASE3","title":"Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer","status":"COMPLETED","sponsor":"CMX Research","startDate":"2007-01","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT00577720","phase":"PHASE2","title":"Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-07","conditions":"Postmenopausal Women","enrollment":181},{"nctId":"NCT00386360","phase":"PHASE3","title":"Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-04","conditions":"Osteopenia","enrollment":161},{"nctId":"NCT00136058","phase":"PHASE3","title":"Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2002-01","conditions":"Osteoporosis","enrollment":250},{"nctId":"NCT01249261","phase":"PHASE3","title":"Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2001-10","conditions":"Postmenopausal Women With Osteoporosis","enrollment":61},{"nctId":"NCT00619957","phase":"PHASE3","title":"Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2002-06","conditions":"Other Osteoporosis","enrollment":285},{"nctId":"NCT00755872","phase":"PHASE1","title":"Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2007-11","conditions":"Bioavailability","enrollment":76},{"nctId":"NCT00717145","phase":"PHASE1","title":"Food Effects on the Relative Bioavailability of Different Dosages of Risedronate","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2008-07","conditions":"Postmenopausal, Non-lactating, Surgically Sterile","enrollment":94},{"nctId":"NCT00868907","phase":"PHASE1","title":"Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-03","conditions":"Healthy","enrollment":101},{"nctId":"NCT00846196","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-01","conditions":"Osteoporosis","enrollment":538},{"nctId":"NCT00460733","phase":"PHASE4","title":"SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Colles' Fracture","enrollment":141},{"nctId":"NCT00577421","phase":"PHASE3","title":"Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2003-06","conditions":"Postmenopausal Osteoporosis","enrollment":32},{"nctId":"NCT00343252","phase":"PHASE3","title":"Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-06","conditions":"Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture","enrollment":712},{"nctId":"NCT00082277","phase":"PHASE4","title":"Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Breast Cancer","enrollment":237},{"nctId":"NCT00130403","phase":"PHASE4","title":"OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-03","conditions":"Osteoporosis, Postmenopausal","enrollment":290},{"nctId":"NCT00268632","phase":"PHASE3","title":"IMPACT Study (Improving Measurements of Persistence on \"ACtonel\" Treatment)","status":"COMPLETED","sponsor":"Sanofi","startDate":"1999-08","conditions":"Osteoporosis","enrollment":""},{"nctId":"NCT00790101","phase":"PHASE4","title":"Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2004-06","conditions":"Osteoporosis, Postmenopausal","enrollment":6},{"nctId":"NCT00138866","phase":"PHASE3","title":"Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury","status":"COMPLETED","sponsor":"Toronto Rehabilitation Institute","startDate":"2004-11","conditions":"Osteoporosis","enrollment":46},{"nctId":"NCT01215890","phase":"PHASE4","title":"Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease","status":"COMPLETED","sponsor":"University of Alberta","startDate":"","conditions":"Crohn's Disease, Low Bone Mineral Density","enrollment":""},{"nctId":"NCT00353080","phase":"PHASE3","title":"Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-12","conditions":"Osteoporosis, Postmenopausal","enrollment":171},{"nctId":"NCT00358176","phase":"PHASE3","title":"Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Osteoporosis Postmenopausal","enrollment":1231},{"nctId":"NCT00345644","phase":"PHASE3","title":"Risedronate in Osteopenic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Osteoporosis","enrollment":156},{"nctId":"NCT00549068","phase":"PHASE4","title":"POWER Point of Care Effect on Satisfaction of Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-02","conditions":"Osteoporosis, Postmenopausal","enrollment":2433},{"nctId":"NCT00544180","phase":"PHASE4","title":"ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week","status":"TERMINATED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Osteoporosis","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risedronate Sodium (Actonel)","genericName":"Risedronate Sodium (Actonel)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risedronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on the bone surface and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Postmenopausal osteoporosis (treatment and prevention), Glucocorticoid-induced osteoporosis, Paget's disease of bone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}